RelA-ASSOCIATED INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF

Abstract

Human RelA-associated inhibitor (RAI) comprising 351 amino acid, process for producing it, cDNA encoding it, fragment capable of hybridizing selectively to the cDNA sequence, plasmid for expression and duplication comprising the cDNA, host cell transformed with the plasmid, antibody against the polypeptide, pharmaceutical composition comprising the polypeptide or the antibody against it and method for diagnosis of diseases using the antibody against the RAI. RAI of the invention is capable of binding to p65, which is a of transcription factor NFκB, therefore, it is thought to be useful for treatment and/or prevention of various diseases.

1 . A polypeptide that comprising an amino acid sequence shown in SEQ ID NO. 1 in substantially purified form, homologue thereof, fragment thereof or homologue of the fragment.  
     
     
         2 . A polypeptide according to  claim 1  that comprising an amino acid sequence shown in SEQ ID NO. 1.  
     
     
         3 . The RelA-associated inhibitor comprising the polypeptide according to  claim 1 .  
     
     
         4 . A cDNA encoding the polypeptide according to  claim 3 .  
     
     
         5 . A cDNA according to  claim 4  that comprising a nucleotide sequence shown in SEQ ID NO. 2 or a fragment capable of hybridizing selectively to the sequence.  
     
     
         6 . A cDNA according to  claim 4  that comprising a nucleotide sequence shown in SEQ ID NO. 3 or a fragment capable of hybridizing selectively to the sequence.  
     
     
         7 . A replication or expression vector carrying the cDNA according to any one of  claims 4  to  6 .  
     
     
         8 . A host cell transformed with the replication or expression vector according to  claim 7 .  
     
     
         9 . A method for producing the polypeptide according to any one of  claims 1  to  3  which comprises culturing a host cell according to  claim 8  under a condition effective to express the said polypeptide.  
     
     
         10 . A monoclonal or polyclonal antibody against the polypeptide according to any one of  claims 1  to  3 .  
     
     
         11 . A pharmaceutical composition comprising the polypeptide according to any one of  claims 1  to  3 , the antibody according to  claim 9  or antisence thereof, in association with pharmaceutically acceptable diluent and/or carrier.  
     
     
         12 . A method for diagnosis of adult respiratory distress syndrome, asthma, Allograft rejection, inflammatory diseases, ischemic diseases, autoimmune diseases including chronic rheumatism, metastasis and invasion of cancer, vasoreconstriction and diseases induced by NFκB besides the above diseases which is characterized by determining the RelA-associated inhibitor activity of the polypeptide according to any one of  claims 1  to  3 .  
     
     
         13 . A method for diagnosis of adult respiratory distress syndrome, asthma, Allograft rejection, inflammatory diseases (inflammatory arthritis, angitis etc.), ischemic diseases, autoimmune diseases including chronic rheumatism, metastasis and invasion of cancer, vasoreconstriction and diseases induced by NFκB besides the above diseases which is characterized by using the antibody according to  claim 10.